## Claim 1 (Currently amended). A compound of the following formula:

HO 
$$R_2$$
  $R_{15}$   $R_{16}$   $VII$ 

wherein R2 and R4 are each independently H [[, ]] alkyl, halogen;

R<sub>15</sub> is amino, or of the following formula:

and R<sub>16</sub> are each

independently is H, alkyl, acyl, alkoxy, aryl, amino, halogen;

and pharmaceutically acceptable salts and prodrugs thereof.

Claims 2-8 (Canceled).

Claim 9 (Original). A compound of claim 1, wherein R<sub>16</sub> is HET.

Claim 10 (Original). A compound of claim 9, wherein HET is pyrrolidine, morpholine.

## Claim 11 (Previously Presented). A compound of claim 1 having the following structure:

Claim 12 (Previously Presented). A hormone replacement therapy regimen comprising: co-administering a therapeutically effective amount of a combination of mammalian estrogen and a compound of claim 1 and a pharmaceutically acceptable carrier to a woman having reduced levels of endogenous estrogen.

Claim 13 (Previously Presented). A method for inhibiting or treating coronary heart disease, cardiovascular disease, comprising:

administering a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier to a patient in need thereof.

Claim 14 (Previously Presented). A method of inhibiting or treating osteoporosis, comprising:

administering a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier to a patient in need thereof.

Claim 15 (Previously Presented). A method of inhibiting or treating gastrointestinal disease, comprising:

administering a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier to a patient in need thereof.

Claim 16 (Previously Presented). A method of inhibiting or treating amebic infections, including giardiasis, comprising:

administering a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier to a patient in need thereof.